Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.

Garber HR, Litton JK.

Curr Opin Oncol. 2019 May;31(3):247-255. doi: 10.1097/CCO.0000000000000516.

PMID:
30789866
2.

Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes.

Alatrash G, Qiao N, Zhang M, Zope M, Perakis AA, Sukhumalchandra P, Philips AV, Garber HR, Kerros C, St John LS, Khouri MR, Khong H, Clise-Dwyer K, Miller LP, Wolpe S, Overwijk WW, Molldrem JJ, Ma Q, Shpall EJ, Mittendorf EA.

Clin Cancer Res. 2019 Apr 15;25(8):2610-2620. doi: 10.1158/1078-0432.CCR-18-1527. Epub 2019 Jan 15.

PMID:
30647079
3.

Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation.

Yang TH, St John LS, Garber HR, Kerros C, Ruisaard KE, Clise-Dwyer K, Alatrash G, Ma Q, Molldrem JJ.

J Immunol. 2018 Sep 1;201(5):1389-1399. doi: 10.4049/jimmunol.1800324. Epub 2018 Jul 18.

4.

Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.

Alatrash G, Perakis AA, Kerros C, Peters HL, Sukhumalchandra P, Zhang M, Jakher H, Zope M, Patenia R, Sergeeva A, Yi S, Young KH, Philips AV, Cernosek AM, Garber HR, Qiao N, Weng J, St John LS, Lu S, Clise-Dwyer K, Mittendorf EA, Ma Q, Molldrem JJ.

Clin Cancer Res. 2018 Jul 15;24(14):3386-3396. doi: 10.1158/1078-0432.CCR-17-2626. Epub 2018 Apr 16.

5.

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA.

NPJ Genom Med. 2017;2. pii: 10. doi: 10.1038/s41525-017-0013-8. Epub 2017 Apr 7.

6.

Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.

Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, St John LS, Federico L, Meraz IM, Roth JA, Sepesi B, Majidi M, Ruisaard K, Clise-Dwyer K, Roszik J, Gibbons DL, Heymach JV, Swisher SG, Bernatchez C, Alatrash G, Hanash S, Molldrem JJ.

Cancer Immunol Res. 2017 Apr;5(4):319-329. doi: 10.1158/2326-6066.CIR-16-0141. Epub 2017 Mar 2.

7.

Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target.

Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, Perakis AA, Becker L, Yoo SY, Dwyer KC, Coombes K, Talukder AH, John LSS, Senyukov V, Lee DA, Sergeeva A, He H, Ma Q, Armistead PM, Roszik J, Mittendorf EA, Molldrem JJ, Hawke D, Lizee G, Kornblau SM.

Leukemia. 2017 Jan;31(1):234-237. doi: 10.1038/leu.2016.249. Epub 2016 Aug 30. No abstract available.

8.

PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.

St John LS, Wan L, He H, Garber HR, Clise-Dwyer K, Alatrash G, Rezvani K, Shpall EJ, Bollard CM, Ma Q, Molldrem JJ.

Cytotherapy. 2016 Aug;18(8):995-1001. doi: 10.1016/j.jcyt.2016.05.007.

9.

Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.

Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1792-1800. doi: 10.1016/j.bbmt.2016.06.023. Epub 2016 Jul 1.

10.

A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.

Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, Sergeeva A, Wood MS, Dotti G, Salvado B, Ruisaard K, Clise-Dwyer K, John LS, Rezvani K, Alatrash G, Shpall EJ, Molldrem JJ.

Cytotherapy. 2016 Aug;18(8):985-994. doi: 10.1016/j.jcyt.2016.05.001. Epub 2016 Jun 2.

11.

Thymic expression of a T-cell receptor targeting a tumor-associated antigen coexpressed in the thymus induces T-ALL.

Cui Y, Onozawa M, Garber HR, Samsel L, Wang Z, McCoy JP, Burkett S, Wu X, Aplan PD, Mackall CL.

Blood. 2015 May 7;125(19):2958-67. doi: 10.1182/blood-2014-10-609271. Epub 2015 Mar 26.

12.

Adoptive T-cell therapy for Leukemia.

Garber HR, Mirza A, Mittendorf EA, Alatrash G.

Mol Cell Ther. 2014 Aug 12;2:25. doi: 10.1186/2052-8426-2-25. eCollection 2014. Review.

13.

Targeting the MAGE A3 antigen in pancreatic cancer.

Cogdill AP, Frederick DT, Cooper ZA, Garber HR, Ferrone CR, Fiedler A, Rosenberg L, Thayer SP, Warshaw AL, Wargo JA.

Surgery. 2012 Sep;152(3 Suppl 1):S13-8. doi: 10.1016/j.surg.2012.05.031. Epub 2012 Jul 6.

Supplemental Content

Loading ...
Support Center